Last SFr.90.75 CHF
Change Today +2.70 / 3.07%
Volume 34.2K
SANN On Other Exchanges
SANN is not on other exchanges.
As of 11:43 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

santhera pharmaceuticals-reg (SANN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - SFr.104.90
52 Week Low
11/22/13 - SFr.3.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

santhera pharmaceuticals-reg (SANN) Related Businessweek News

No Related Businessweek News Found

santhera pharmaceuticals-reg (SANN) Details

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications in North America and the EU. The company offers Raxone/Catena for the treatment of Friedreich’s Ataxia. Its products under development include Raxone/Catena, which is in preparation for regulatory re-submission marketing authorization in Europe for Leber's Hereditary Optic Neuropathy, in a Phase III study for Duchenne Muscular Dystrophy, and in a Phase II study for Primary Progressive Multiple Sclerosis; omigapil that is in Phase I pharmacokinetics study in pediatric patients with Congenital Muscular Dystrophy; and Fipamezole, which has completed Phase IIb study for treatment of Dyskinesia in Parkinson's disease. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.

11.8 Employees
Last Reported Date: 04/7/14
Founded in 2004

santhera pharmaceuticals-reg (SANN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.326.4K
Compensation as of Fiscal Year 2013.

santhera pharmaceuticals-reg (SANN) Key Developments

Santhera Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the First Six Months Ended June 30, 2014

Santhera Pharmaceuticals reported unaudited consolidated earnings results for the first six months ended June 30, 2014. For the period, the company reported net sales were CHF 0.8 million, mainly driven by the first sales of Raxone for LHON under the cATU in France as well as sales for DMD and LHON patients under named patient and special access programs. As a result, the company narrowed its operating loss to CHF 3.1 million against CHF 4.8 million a year ago. The company reported an improved net result negative of CHF 3.1 million against CHF 3.2 million, which included extraordinary financial income of CHF 1.5 million from the settlement of finance lease liabilities. Basic and diluted loss per share was CHF 0.70 against CHF 0.88 a year ago. Operating cash flow negative was CHF 2,572,000 against CHF 4,119,000 a year ago. Financial result negative was CHF 101,569,000.

Santhera Pharmaceuticals Holding AG to Report Q2, 2014 Results on Sep 09, 2014

Santhera Pharmaceuticals Holding AG announced that they will report Q2, 2014 results on Sep 09, 2014

Santhera Pharmaceuticals Reports Positive Outcome for Catena(R)/Raxone(R) in Phase III DMD Trial Supported by Additional Respiratory Function Data

Santhera Pharmaceuticals reported that the results of secondary respiratory function endpoints from the on-going analysis of the DELOS trial in Duchenne Muscular Dystrophy (DMD) corroborate the positive outcome for the primary endpoint. These data provide further supportive evidence of a treatment benefit for Catena(R)/Raxone(R) in DMD. As previously announced, the DELOS trial met the primary endpoint, the difference between Catena(R)/Raxone(R) and placebo in the change from baseline to week 52 in Peak Expiratory Flow (PEF as percent predicted, PEF%p). Hospital-based spirometry assessments demonstrated that Catena(R)/Raxone(R) significantly reduced the annual decline in PEF%p by 66% compared to patients taking placebo. The average annual decline in PEF%p was 9.0% for placebo (Baseline: 54.3%; Week 52: 45.3% (n=27), p<0.001) versus 3.1% for Catena(R)/Raxone(R) (Baseline PEF%P: 53.1%; Week 52: 50.1% (n=30); p=0.13) for a treatment group difference in change from Baseline to Week 52 of 5.96% (p=0.04).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANN:SW SFr.90.75 CHF +2.70

SANN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SANN.
View Industry Companies

Industry Analysis


Industry Average

Valuation SANN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 370.3x
Price/Book 56.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 409.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTHERA PHARMACEUTICALS-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at